139 related articles for article (PubMed ID: 24297682)
1. First-in-human phase II trial of the botanical formulation PHY906 with capecitabine as second-line therapy in patients with advanced pancreatic cancer.
Saif MW; Li J; Lamb L; Kaley K; Elligers K; Jiang Z; Bussom S; Liu SH; Cheng YC
Cancer Chemother Pharmacol; 2014 Feb; 73(2):373-80. PubMed ID: 24297682
[TBL] [Abstract][Full Text] [Related]
2. Phase I study of the botanical formulation PHY906 with capecitabine in advanced pancreatic and other gastrointestinal malignancies.
Saif MW; Lansigan F; Ruta S; Lamb L; Mezes M; Elligers K; Grant N; Jiang ZL; Liu SH; Cheng YC
Phytomedicine; 2010 Mar; 17(3-4):161-9. PubMed ID: 20092990
[TBL] [Abstract][Full Text] [Related]
3. Phase I/II study of PHY906/capecitabine in advanced hepatocellular carcinoma.
Yen Y; So S; Rose M; Saif MW; Chu E; Liu SH; Foo A; Jiang Z; Su T; Cheng YC
Anticancer Res; 2009 Oct; 29(10):4083-92. PubMed ID: 19846955
[TBL] [Abstract][Full Text] [Related]
4. A phase II study of capecitabine plus docetaxel in gemcitabine-pretreated metastatic pancreatic cancer patients: CapTere.
Soares HP; Bayraktar S; Blaya M; Lopes G; Merchan J; Macintyre J; Mayo C; Green MR; Silva O; Levi J; Walker G; Rocha-Lima CM
Cancer Chemother Pharmacol; 2014 Apr; 73(4):839-45. PubMed ID: 24562589
[TBL] [Abstract][Full Text] [Related]
5. A Phase II Clinical Trial on the Combination Therapy of PHY906 Plus Capecitabine in Hepatocellular Carcinoma.
Changou CA; Shiah HS; Chen LT; Liu S; Luh F; Liu SH; Cheng YC; Yen Y
Oncologist; 2021 Mar; 26(3):e367-e373. PubMed ID: 33140457
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced pancreatic cancer.
Kordes S; Klümpen HJ; Weterman MJ; Schellens JH; Richel DJ; Wilmink JW
Cancer Chemother Pharmacol; 2015 Jun; 75(6):1135-41. PubMed ID: 25822310
[TBL] [Abstract][Full Text] [Related]
7. Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second-line therapy for patients with advanced pancreatic cancer.
Xiong HQ; Varadhachary GR; Blais JC; Hess KR; Abbruzzese JL; Wolff RA
Cancer; 2008 Oct; 113(8):2046-52. PubMed ID: 18756532
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of capecitabine in combination with docetaxel and mitomycin C in patients with pre-treated pancreatic, gallbladder, and bile duct carcinoma.
Kruth J; Nissen J; Ernst T; Kripp M; Lukan N; Merx K; Hofmann WK; Hochhaus A; Hofheinz RD
J Cancer Res Clin Oncol; 2010 Dec; 136(12):1845-51. PubMed ID: 20224968
[TBL] [Abstract][Full Text] [Related]
9. Phase I dose escalation study of capecitabine and erlotinib concurrent with radiation in locally advanced pancreatic cancer.
Jiang Y; Mackley HB; Kimchi ET; Zhu J; Gusani N; Kaifi J; Staveley-O'Carroll KF; Belani CP
Cancer Chemother Pharmacol; 2014 Jul; 74(1):205-10. PubMed ID: 24908435
[TBL] [Abstract][Full Text] [Related]
10. A retrospective study of capecitabine/temozolomide (CAPTEM) regimen in the treatment of metastatic pancreatic neuroendocrine tumors (pNETs) after failing previous therapy.
Saif MW; Kaley K; Brennan M; Garcon MC; Rodriguez G; Rodriguez T
JOP; 2013 Sep; 14(5):498-501. PubMed ID: 24018594
[TBL] [Abstract][Full Text] [Related]
11. [Effect of second-line treatment with capecitabine and thalidomide in patients with advanced pancreatic cancer].
Shi SB; Ma TH; Tang XY; Li CH
Zhonghua Zhong Liu Za Zhi; 2013 Apr; 35(4):301-4. PubMed ID: 23985261
[TBL] [Abstract][Full Text] [Related]
12. Phase I trial of capecitabine plus everolimus (RAD001) in patients with previously treated metastatic gastric cancer.
Lim T; Lee J; Lee DJ; Lee HY; Han B; Baek KK; Ahn HK; Lee SJ; Park SH; Park JO; Park YS; Lim HY; Kim KM; Kang WK
Cancer Chemother Pharmacol; 2011 Jul; 68(1):255-62. PubMed ID: 21526353
[TBL] [Abstract][Full Text] [Related]
13. A phase I/II, non-randomized, feasibility/safety and efficacy study of the combination of everolimus, cetuximab and capecitabine in patients with advanced pancreatic cancer.
Kordes S; Richel DJ; Klümpen HJ; Weterman MJ; Stevens AJ; Wilmink JW
Invest New Drugs; 2013 Feb; 31(1):85-91. PubMed ID: 22367239
[TBL] [Abstract][Full Text] [Related]
14. Combining capecitabine and gemcitabine in patients with advanced pancreatic carcinoma: a phase I/II trial.
Hess V; Salzberg M; Borner M; Morant R; Roth AD; Ludwig C; Herrmann R
J Clin Oncol; 2003 Jan; 21(1):66-8. PubMed ID: 12506172
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of bevacizumab-based combination regimens in patients with previously untreated metastatic colorectal cancer: final results from a randomised phase II study of bevacizumab plus 5-fluorouracil, leucovorin plus irinotecan versus bevacizumab plus capecitabine plus irinotecan (FNCLCC ACCORD 13/0503 study).
Ducreux M; Adenis A; Pignon JP; François E; Chauffert B; Ichanté JL; Boucher E; Ychou M; Pierga JY; Montoto-Grillot C; Conroy T
Eur J Cancer; 2013 Apr; 49(6):1236-45. PubMed ID: 23352604
[TBL] [Abstract][Full Text] [Related]
16. Phase 2 trial of paclitaxel polyglumex with capecitabine for metastatic breast cancer.
Northfelt DW; Allred JB; Liu H; Hobday TJ; Rodacker MW; Lyss AP; Fitch TR; Perez EA;
Am J Clin Oncol; 2014 Apr; 37(2):167-71. PubMed ID: 23211220
[TBL] [Abstract][Full Text] [Related]
17. Second-line chemotherapy with capecitabine (Xeloda) and docetaxel (Taxotere) in previously treated, unresectable adenocarcinoma of pancreas: the final results of a phase II trial.
Katopodis O; Polyzos A; Kentepozidis N; Giassas S; Rovithi M; Bozionelou V; Kalbakis K; Vamvakas L; Mavroudis D; Georgoulias V
Cancer Chemother Pharmacol; 2011 Feb; 67(2):361-8. PubMed ID: 20428874
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of lapatinib and capecitabine in second-line treatment for metastatic pancreatic cancer.
Wu Z; Gabrielson A; Hwang JJ; Pishvaian MJ; Weiner LM; Zhuang T; Ley L; Marshall JL; He AR
Cancer Chemother Pharmacol; 2015 Dec; 76(6):1309-14. PubMed ID: 26507197
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of oral vinorelbine in combination with capecitabine as second line chemotherapy in metastatic breast cancer patients previously treated with anthracyclines and taxanes.
Jones A; O'Brien M; Sommer H; Nowara E; Welt A; Pienkowski T; Rolski J; Pham ML; Perraud K; Trillet-Lenoir V
Cancer Chemother Pharmacol; 2010 Mar; 65(4):755-63. PubMed ID: 19669644
[TBL] [Abstract][Full Text] [Related]
20. Gemcitabine plus capecitabine in unselected patients with advanced pancreatic cancer.
Hubner RA; Worsnop F; Cunningham D; Chau I
Pancreas; 2013 Apr; 42(3):511-5. PubMed ID: 23462324
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
